Raymond (NSE:RYMD) James has upgraded Humana’s stock rating from Market Perform to Outperform, setting a new price target of $315, citing the company’s strong performance and favorable drug mix.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

While robust first-quarter earnings and operational performance were reported ... Unlock comprehensive insights into our analysis of Humana stock in this financial health report.

Shares of Humana Inc. rallied 3.94% to $247.34 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.09% to 5,963.60 and the Dow ...

The performance and reduced forecast led to a ... The warning about healthcare costs dragged other insurer stocks, with Humana (HUM), CVS Health (CVS), and Elevance Health (ELV) also among the ...

Humana Inc. closed 43.21% below its 52-week high of $406.46, which the company reached on July 18th.

U.S. equities edged higher midday after the House passed the big tax and spending package supported by President Trump.

JPMorgan Chase & Co. dropped their price target on Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. Robert W. Baird ...